Table 1.
Characteristics of patients in the ACTG A5095 trial, and persons with HIV diagnosed in the United States during 2008–2014.
| Characteristics | ZDV/3TC + EFV | ZDV/3TC/ABC + EFV | Total | Recently HIV-diagnosed persons in the USA, 2008–2014 |
|---|---|---|---|---|
| Total N | 380 | 381 | 761 | 296,073 |
| Sex, no. (%) | ||||
| Men | 314 (83) | 302 (79) | 616 (81) | 232,933 (79) |
| Age group, no. (%), y | ||||
| <26 | 32 (8) | 36 (9) | 68 (9) | 59,274 (20) |
| 26–50 | 318 (84) | 310 (81) | 628 (83) | 209,289 (70)a |
| >50 | 30 (8) | 35 (9) | 65 (9) | 27,510 (9) |
| Intravenous drug useb, no. (%) | ||||
| Ever | 37 (9) | 46 (12) | 82 (11) | 23,134 (8) |
| HIV-1 RNA (copies/mL) | ||||
| log10 | ||||
| Median (IQR) | 4.75 (4.43–5.43) | 4.78 (4.33–5.38) | 4.77 (4.38–5.41) | |
| No. (%) | ||||
| <10,000 | 30 (9) | 41 (11) | 71 (9) | |
| 10,000–100,000 | 201 (53) | 188 (49) | 389 (51) | |
| >100,000 | 149 (39) | 152 (40) | 301 (40) | |
| CD4 cell count, cells/mm3 | ||||
| Median (IQR) | 209 (77–331) | 223 (79–339) | 214 (78–334) | |
| No. (%) | ||||
| 0–50 | 80 (21) | 72 (19) | 152 (20) | |
| 51–200 | 102 (27) | 104 (27) | 206 (27) | |
| 201–500 | 165 (43) | 168 (44) | 333 (44) | |
| >500 | 33 (9) | 37 (10) | 70 (9) | |
| HBV/HCV infectionc, no. (%) | ||||
| Positive | 50 (13) | 48 (13) | 98 (14) |
HIV, human immunodeficiency virus; IQR, interquartile range; SD, standard deviation; ZDV, zidovudine; 3TC, lamivudine; ABC, abacavir; EFV, efavirenz; HBV, hepatitis B virus; HCV; hepatitis C virus.
a
The number and percentage of persons at age 25–54 years in the US recently HIV-diagnosed population.
b
Only one patient in ZDV/3TC + EFV arm was current intravenous drug user.
c
HBV infection was defined as the presence of hepatitis B surface antigen; HCV infection was defined as the presence of hepatitis C antibody.